Aptamer Group
Aptamer Group is a leading provider of Optimer® binders for use in therapeutics, diagnostics, bioprocessing and research. The Company strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer® technology.
Latest Aptamer Group Content
Product News
Aptamer Extends Agreement With Genetic Medicines Customer
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders, is pleased to announce that a genetic medicines customer has selected to progress to the final commercial development phase for Optimer delivery vehicles.
Product News
Partnership With Microsaic Systems for Optimer-Enabled Water Monitoring
New binders will be developed to multiple waterborne pathogens. Optimer will support continuous water monitoring for rapid detection.
Product News
Aptamer and Timser Partner To Deliver World’s First Blood Test for Cervical Cancer
Optimer binders will be developed for use in a cervical cancer blood test. Agreement for up to £465,000 signed for Optimer development.
Product News
Top Pharmaceutical Company Evaluates Optimer for Precision Liver Medicine
Optimer delivery vehicle has been shipped to a pharma partner for external evaluation. The specific delivery vehicle could generate new precision therapies for liver disease.
Product News
Aptamer and Kairos Biotech Partner for Optimer+ Transplant Rejection Therapies
Partnership will use the new Optimer+ platform. Optimer+ EM molecules to be developed to help prevent transplant rejection.
Product News
Patent Submission for Optimer® Binders in Cosmetic Products
Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces that it has filed a patent application to protect the recently developed Optimer binder sequences for novel applications.
Advertisement
